JP2005518357A5 - - Google Patents

Download PDF

Info

Publication number
JP2005518357A5
JP2005518357A5 JP2003545654A JP2003545654A JP2005518357A5 JP 2005518357 A5 JP2005518357 A5 JP 2005518357A5 JP 2003545654 A JP2003545654 A JP 2003545654A JP 2003545654 A JP2003545654 A JP 2003545654A JP 2005518357 A5 JP2005518357 A5 JP 2005518357A5
Authority
JP
Japan
Prior art keywords
formula
alkyl
independently
nitrogen
pharmaceutical salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003545654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005518357A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/033625 external-priority patent/WO2003044017A1/en
Publication of JP2005518357A publication Critical patent/JP2005518357A/ja
Publication of JP2005518357A5 publication Critical patent/JP2005518357A5/ja
Pending legal-status Critical Current

Links

JP2003545654A 2001-11-20 2002-11-12 ベータ3アドレナリンアゴニスト Pending JP2005518357A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33403101P 2001-11-20 2001-11-20
PCT/US2002/033625 WO2003044017A1 (en) 2001-11-20 2002-11-12 Beta 3 adrenergic agonists

Publications (2)

Publication Number Publication Date
JP2005518357A JP2005518357A (ja) 2005-06-23
JP2005518357A5 true JP2005518357A5 (enExample) 2006-01-05

Family

ID=23305278

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545654A Pending JP2005518357A (ja) 2001-11-20 2002-11-12 ベータ3アドレナリンアゴニスト

Country Status (8)

Country Link
US (4) US7071208B2 (enExample)
EP (1) EP1448561B1 (enExample)
JP (1) JP2005518357A (enExample)
AT (1) ATE386740T1 (enExample)
AU (1) AU2002353844A1 (enExample)
DE (1) DE60225174T2 (enExample)
ES (1) ES2299618T3 (enExample)
WO (1) WO2003044017A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1421078B1 (en) * 2001-08-14 2006-09-27 Eli Lilly And Company Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes
JP2005518357A (ja) * 2001-11-20 2005-06-23 イーライ・リリー・アンド・カンパニー ベータ3アドレナリンアゴニスト
DE60204718T2 (de) * 2001-11-20 2006-05-18 Eli Lilly And Co., Indianapolis 3-substituierte oxindol beta 3 agonisten
JP4618250B2 (ja) * 2003-12-23 2011-01-26 アステラス製薬株式会社 アミノアルコール誘導体
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
JP2008100916A (ja) * 2005-01-24 2008-05-01 Dainippon Sumitomo Pharma Co Ltd インドール類およびそれを含む医薬組成物
JP4864982B2 (ja) * 2005-12-27 2012-02-01 エフ.ホフマン−ラ ロシュ アーゲー アリール−イソオキサゾール−4−イル−イミダゾ[1,5−a]ピリジン誘導体
WO2007137954A1 (en) 2006-05-31 2007-12-06 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
MX2009014001A (es) 2007-06-22 2010-01-28 Hoffmann La Roche Derivados de isoxazol-imidazol.
US7902201B2 (en) 2007-12-04 2011-03-08 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
EP2229383B1 (en) 2007-12-04 2017-01-18 F. Hoffmann-La Roche AG Isoxazolo-pyrazine derivatives
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US20100280019A1 (en) 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles
JP5466292B2 (ja) 2009-05-05 2014-04-09 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾール−ピリジン誘導体
EP2427459B1 (en) 2009-05-05 2016-09-28 F. Hoffmann-La Roche AG Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
SG175333A1 (en) 2009-05-05 2011-12-29 Hoffmann La Roche Isoxazole-pyrazole derivatives
KR101701533B1 (ko) 2009-05-05 2017-02-13 에프. 호프만-라 로슈 아게 아이속사졸-피리다진 유도체
CA2757412C (en) 2009-05-07 2016-04-05 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives as gaba modulators
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
CN111108105B (zh) 2017-09-22 2023-03-31 朱比兰特埃皮帕德有限公司 作为pad抑制剂的杂环化合物
KR102782563B1 (ko) 2017-10-18 2025-03-14 주빌런트 에피파드 엘엘씨 Pad 억제제로서의 이미다조-피리딘 화합물
AU2018362046B2 (en) 2017-11-06 2023-04-13 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
HUE067265T2 (hu) 2017-11-24 2024-10-28 Jubilant Episcribe Llc Heterociklusos vegyületek mint PRMT5 inhibitorok
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2023114844A1 (en) * 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Imidazopyridine psychoplastogens and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624395A5 (enExample) 1976-01-08 1981-07-31 Ciba Geigy Ag
CA1116598A (en) 1977-07-13 1982-01-19 William T. Comer 3-indolyl-tertiary butylaminopropanols
US4234595A (en) 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
US4314943A (en) 1977-07-13 1982-02-09 Mead Johnson & Company Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
JPS6010021B2 (ja) 1979-01-31 1985-03-14 田辺製薬株式会社 新規ベンジルアルコ−ル誘導体及びその製法
DE3423429A1 (de) 1984-06-26 1986-01-02 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
DE3426419A1 (de) 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4728651A (en) 1985-10-24 1988-03-01 Hoechst-Roussel Pharmaceuticals Inc. Antihypertensive thieno-isoxazoles and -pyrazoles
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
NO303782B1 (no) 1994-03-23 1998-08-31 Sankyo Co Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
WO1997046556A1 (en) 1996-06-07 1997-12-11 Merck & Co., Inc. OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
US5808080A (en) 1996-09-05 1998-09-15 Eli Lilly And Company Selective β3 adrenergic agonists
ES2171839T3 (es) 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
US6011048A (en) 1997-01-28 2000-01-04 Merck & Co., Inc. Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
PL334833A1 (en) 1997-01-28 2000-03-27 Merck & Co Inc Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
JP2003055344A (ja) * 1999-01-29 2003-02-26 Dainippon Pharmaceut Co Ltd 3,7−ジ置換インドール誘導体及びそれを含有する医薬組成物
AU6050000A (en) 1999-07-22 2001-02-13 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
WO2001035947A2 (en) 1999-11-15 2001-05-25 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines
WO2001036412A1 (en) 1999-11-15 2001-05-25 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
US6420365B1 (en) * 2000-01-18 2002-07-16 Neurogen Corporation Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors
HRP20030018A2 (en) 2000-07-13 2003-04-30 Lilly Co Eli Beta3 adrenergic agonists
IL154928A0 (en) 2000-11-10 2003-10-31 Lilly Co Eli 3-substituted oxindole beta 3 agonists
ATE325119T1 (de) 2001-08-14 2006-06-15 Lilly Co Eli 3-substituierte oxindol-beta-3-agonisten
EP1421078B1 (en) 2001-08-14 2006-09-27 Eli Lilly And Company Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes
DE60204718T2 (de) 2001-11-20 2006-05-18 Eli Lilly And Co., Indianapolis 3-substituierte oxindol beta 3 agonisten
JP2005518357A (ja) 2001-11-20 2005-06-23 イーライ・リリー・アンド・カンパニー ベータ3アドレナリンアゴニスト

Similar Documents

Publication Publication Date Title
JP2005518357A5 (enExample)
JP2005514366A5 (enExample)
JP2005507872A5 (enExample)
JP2006524225A5 (enExample)
JP2007508359A5 (enExample)
JP2008514732A5 (enExample)
JP2006524222A5 (enExample)
JP2008543886A5 (enExample)
JP2009515980A5 (enExample)
JP2006515339A5 (enExample)
JP2005500311A5 (enExample)
JP2010510233A5 (enExample)
JP2006517572A5 (enExample)
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
IL189069A0 (en) Piperidine and piperazine derivatives as p2x3 antagonists
IL185844A0 (en) I-acetic acid-indole derivatives with pgd2 antagonist activity
JP2010513322A5 (enExample)
JP2010504286A5 (enExample)
JP2005517643A5 (enExample)
JP2012505234A5 (enExample)
JP2007501831A5 (enExample)
JP2021501208A5 (enExample)
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
JP2007510662A5 (enExample)
JP2005525392A5 (enExample)